The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of ...
AstraZeneca is a leader in cancer treatments with FDA-approved drugs. Read why AZN stock is still a 'Buy' and why the company’s future looks bright.
GlobalData on MSN13d
JP Morgan 2025: AstraZeneca promises a ‘catalyst-rich’ year aheadCFO Aradhana Sarin outlined AstraZeneca’s plans at the 2025 JP Morgan Healthcare Conference in San Francisco on 15 January. The company maintains a confident outlook for the new year, said Sarin, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback